Induction of liver cytochrome P450 1A2 expression by flutamide in rats

被引:0
作者
Hai-xue Wang
Xiao Liu
Chang-jiang Xu
Xiao-chao Ma
Jian-er Long
Duan Li
机构
[1] School of Pharmacy,Department of Pharmacology
[2] Fudan University,undefined
[3] State Key Laboratory of Drug Research,undefined
[4] Shanghai Institute of Biological Sciences,undefined
[5] Shanghai Institute of Materia Medica,undefined
[6] Chinese Academy of Sciences,undefined
[7] Institute of Molecular Virus,undefined
[8] School of Basic Medical Science,undefined
[9] Fudan University,undefined
来源
Acta Pharmacologica Sinica | 2005年 / 26卷
关键词
flutamide; cytochrome P450 1A2; induction;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1382 / 1386
页数:4
相关论文
共 101 条
[1]  
Neri RO(1972)A biological profile of a nonsteroidal antiandrogen, SCH13521(4′-nitro-3′trifluoromethyliso-butyranilide). Endocrinology 91 427-37
[2]  
Florance K(1972)Effects of novel nonsteroidal antiandrogen on canine prostatic hyperplasia. Invest Urol 10 123-30
[3]  
Koziol P(1989)Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer. J Steroid Biochem 33 817-21
[4]  
Neri RO(2004)Microarray analysis of changes in renal phenotype in the ethylene glycol rat model of urolithiasis: potential and pitfalls. BJU Int 93 637-50
[5]  
Monahan M(2004)The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. BJU Int 93 1119-20
[6]  
Labrie F(1999)Fulminant liver failure associated with flutamide therapy for hirsutism. Lancet 353 983-6
[7]  
Dupont A(1975)The treatment of benign prostatic hypertrophy with flutamide: a placebo controlled study. J Urol 114 564-6
[8]  
Cusan L(1975)Placebo-controlled double-blind study in human benign obstructive prostatic hypertrophy with flutamide. Eur Urol 2 24-8
[9]  
Manhes G(2004)Toxic hepatitis and liver failure under therapy with flutamide. Internist (Berl) 45 333-40
[10]  
Bergeron N(1992)Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 92 465-70